Goldman Sachs Maintains Neutral on Fulcrum Therapeutics, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Madhu Kumar has maintained a Neutral rating on Fulcrum Therapeutics (NASDAQ: FULC) and increased the price target from $5 to $6.
January 25, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on Fulcrum Therapeutics but raises the price target from $5 to $6.
The increase in price target by a reputable analyst like Goldman Sachs suggests a positive outlook on the stock's value, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100